U-Ms academic medical center, Michigan Medicine, is working with AstraZeneca to carry out the third trial phase of a potential vaccine for COVID-19.
The University of Michigan is one of multiple U.S. sites testing the investigational vaccine against COVID-19.
Officials say the phase three clinical trial is expected to include about 30,000 participants in total over the course of two years.
We are proud to advance the University of Michigans outstanding legacy of excellence in vaccine trials with this important clinical trial partnership, said Mark Schlissel, M.D., Ph.D., president of the University of Michigan.
For more information, or to volunteer for the vaccine trial, click here.